Quadratus Lumborum Block : Effect on Acute Pain and Quality of Recovery After Laparoscopic Adrenalectomy

Pain Management Clinical Trial

Official title:

Quadratus Lumborum Block : Effect on Acute Pain and Quality of Recovery After Laparoscopic Adrenalectomy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03844477
• Other study ID #: cuixulei6
• Status: Terminated
• Phase: N/A
• Start date: February 16, 2019
• Est. completion date: May 15, 2019

Study information

• Verified date: September 2019
• Source: Peking Union Medical College Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This prospective, randomized ,control study aims to compare the analgesic effect,quality of recovery, length of hospital stay ,et al. between single-injection QLB(quadratus lumborum block)+general anesthesia (GA) and general anesthesia (GA) alone in patients undergoing laparoscopic adrenalectomy.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 25
• Est. completion date: May 15, 2019
• Est. primary completion date: May 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Age 18-70 yrs

• American Society of Anesthesiologists physical status?-?

• Undergo laparoscopic adrenalectomy

• Informed consent

Exclusion Criteria:

• A known allergy to the drugs being used

• Coagulopathy, on anticoagulants

• Analgesics intake, history of substance abuse

• Participating in the investigation of another experimental agent

• Inability to properly describe postoperative pain to investigators (eg, language barrier, neuropsychiatric disorder)

Related Conditions & MeSH terms

• Acute Pain
• Laparoscopic Adrenalectomy
• Nerve Block
• Pain Management

Intervention

Procedure:
• single-injection QLB(quadratus lumborum block)
Inject 0.4ml/kg 0.5% ropivacaine between quadratus lumborum and psoas major without continuous local infusion Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan Device: PAJUNK StimuLong Drug: single dose ropivacaine 0.4ml/kg 0.5% ropivacaine given immediately after the correct position of the tip of the needle has been verified.
• Placebo control
Inject 0.4ml/kg saline between quadratus lumborum and psoas major without continuous local infusion Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan Device: PAJUNK StimuLong Drug: single dose 0.4ml/kg 0.9% NS. given immediately after the correct position of the tip of the needle has been verified.

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	pain numeric rating scale (NRS, 0-10)pain score at activity at 12 hours after surgery		At 12hours after the surgery
Secondary	The pain scores at rest determined by the numeric rating scale (NRS, 0-10)		At 2,4, 8, 12,24 ,48,72hours after the surgery
Secondary	incidence of postoperative nausea and vomiting (PONV)		within 24 postoperative hours
Secondary	ambulation time		within5 days after surgery
Secondary	time of restart anal exhaust		within 5 days after surgery
Secondary	Postoperative length of hospital stay		up to2 weeks after surgery
Secondary	patient's satisfaction with anesthesia and analgesia	use the Chinese version Bauer questionnaire to assess the patient satisfaction with anesthesia and analgesia	48 hours after surgery
Secondary	The pain scores at activity determined by the numeric rating scale (NRS, 0-10)		At 2,4, 8, 24 ,48,72hours after the surgery